An Open Label Expanded Access Program Intended to Provide Treatment with HBS-101 (Pitolisant) to Adult Patients in the U.S. with Excessive Daytime Sleepiness Associated with Narcolepsy with or without Cataplexy
Aims: The purpose of this Expanded Access Program (EAP) is to allow patients who have Excessive Daytime Sleepiness (EDS) associated with narcolepsy with or without cataplexy, access to the medication, pitolisant, prior to FDA marketing approval being granted. This EAP also studies the safety and tolerability of pitolisant in adult patients with this condition.
Principal Investigator: Thomas Freedom, MD
NorthShore Project Number: EH19-028
Contact: Call 847.503.4333 with questions regarding the study
Open to Enrollment: Yes